摘要
[目的]对比分析多西他赛联合表柔比星加/不加环磷酰胺（TEC/TE）两种新辅助化疗方案治疗乳腺癌的近期疗效。[方法]回顾性分析2006~2009年收治的Ⅱ~Ⅲ期乳腺癌新辅助化疗患者108例的临床病理资料,分别术前接受新辅助化疗的TE方案（n=62）及TEC方案（n=46）,两组患者均在术前接受2~4个周期化疗。TE方案：多西他赛75mg/m2,第1天静脉滴注;表柔比星（EPI）60mg/m2,第1天静脉滴注。[结果]全组108例患者均可评价疗效,CR 10例（9.25%）,PR 75例（69.44%）。TE组有效率为75.81%,而TEC组有效率为82.61%,两组有效率无统计学差异（χ2=0.729,P=0.392）。Ⅱ期患者28例均生存。Ⅲ期患者80例3年生存率为82.4%,其中TE组44例3年生存率为74.6%;而TEC组36例3年生存率为91.8%,差异有统计学意义（χ2=4.149,P=0.042）。[结论]在Ⅱ~Ⅲ期乳腺癌患者新辅助化疗中,TE与TEC方案近期疗效相似,TEC组3年生存率较佳,有待于进一步加大样本量进行研究。
[Purpose] To compare the short-term efficacy of two neoadjuvant chemotherapy regimens：TE regimen（docetaxel,epirubicin） versus TEC regimen（docetaxel,epirubicin plus cyclophosphamide）.[Methods] The clinical data of 108 breast cancer patients with stage Ⅱ~Ⅲ from 2006to 2009 were analyzed retrospectively. All the patients received neoadjuvant chemotherapy with TE（n=62） or TEC（n=46） regimen for 2~4 cycles before surgery. [Results] The assessments of 108patients were available, 10 cases achieved CR（9.25%） and 75 cases achieved PR（69.44%）. The response rate of TE group was 75.81%,and TEC group was 82.61% with no significant difference（χ2=0.729,P =0.392）. Twenty-eight patients with stage Ⅱ were all survival during the follow-up.The 3-year overall survival in 80 patients stage Ⅲ was 82.4%, and 3-year overall survival in TE group（n=44） was 74.6% and 82.4% in TEC group（n=36） with significant difference（χ2=4.149,P=0.042）. [Conclusion] The short-term efficacy of TE and TEC neoadjuvant chemotherapy regimens in stage Ⅱ~Ⅲ breast cancer patients are similar. The 3-year overall survival rate might be higher in TEC group. It should be further researched with larger samples.
出处
《中国肿瘤》
CAS
2013年第11期926-930,共5页
China Cancer
关键词
乳腺癌
新辅助化疗
多西他赛
表阿霉素
breast cancer
neoadjuvant chemotherapy
docetaxel
epirubicin
